Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Moderna posts bigger loss than expected as it scales down manufacturing
Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...
Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
News4Jax7h
Unexpected aftermath: Study finds COVID infection increases risk of heart attack, stroke
When COVID-19 swept across the globe, isolation, social distancing and wearing masks became the norm. Since then, more than ...
Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...
Moderna swings to Q4 loss after nearly 66% drop in revenue
Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...
pharmaphorum22h
Blow to Moderna as EU nixes mRNA vaccine patent
The European Patent Office has said it has invalidated a patent held by Moderna on mRNA-based COVID-19 vaccines, the latest development in an increasingly acrimonious dispute between the company ...
cweb6h
Moderna, Inc. (NASDAQ:MRNA) Faces Challenges and Opportunities in Biotech Sector
Moderna’s consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from ...
pharmaphorum22h
BioNTech wins round in CureVac mRNA patent dispute
claiming infringement by their Comirnaty coronavirus shot. CureVac – which is developing mRNA-based vaccines for COVID-19 and influenza with GSK – filed suit in the Düsseldorf Regional Court ...